Recent evidence suggests a class effect of SGLT2 inhibitors, with randomized controlled studies revealing a significant elevation in serum magnesium levels, ranging from 0.04-0.1 mmol/L, in patients with type 2 diabetes, regardless of baseline hypomagnesemia [2,3]. However, the role of SGLT2 inhibitors in treating hypomagnesemia in non-diabetic patients remains unexplored. The gene discussed is SLC5A2; the disease is familial primary hypomagnesemia.